immunotherapy (AstraZeneca/CSL)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Nameimmunotherapy (AstraZeneca/CSL)
Drug Alias NameH pylori therapeutic vaccine (CSL/AstraZeneca)
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsHelicobacter pylori infection
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwedenAustralia and New Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCsl Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstraCsl Ltd
Active IndicationsN/A
Inactive IndicationsHelicobacter pylori infection

Other Information

ATC CodeN/A
Related LinksN/A